- Home
- GMAB vs XPEV Comparison
GMAB vs XPEV Comparison
Compare GMAB & XPEV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GMAB | XPEV |
|---|---|---|
| Founded | 1999 | 2015 |
| Country | Denmark | China |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Auto Manufacturing |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.4B | 20.2B |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | GMAB | XPEV |
|---|---|---|
| Price | $31.78 | $20.04 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 6 | 6 |
| Target Price | ★ $40.40 | $24.90 |
| AVG Volume (30 Days) | 1.4M | ★ 18.2M |
| Earning Date | 11-06-2025 | 11-17-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 132.41 | N/A |
| EPS | ★ 25.10 | N/A |
| Revenue | $3,845,670,022.00 | ★ $9,912,782,208.00 |
| Revenue This Year | $24.85 | $99.25 |
| Revenue Next Year | $16.67 | $39.50 |
| P/E Ratio | $12.31 | ★ N/A |
| Revenue Growth | 29.57 | ★ 86.64 |
| 52 Week Low | $17.24 | $11.14 |
| 52 Week High | $33.65 | $28.24 |
Technical Indicators
Market Signals| Indicator | GMAB | XPEV |
|---|---|---|
| Relative Strength Index (RSI) | 59.84 | 42.33 |
| Support Level | $31.32 | $18.55 |
| Resistance Level | $32.41 | $21.99 |
| Average True Range (ATR) | 0.64 | 0.87 |
| MACD | 0.11 | -0.33 |
| Stochastic Oscillator | 73.67 | 26.04 |
Price Performance
Historical ComparisonAbout GMAB Genmab A/S ADS
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
About XPEV XPeng Inc.
Founded in 2015, XPeng is a leading Chinese smart electric vehicle company that designs, develops, manufactures, and markets EVs in China. Its products primarily target the growing base of technology-savvy middle-class consumers in the midrange to high-end segment in China's passenger vehicle market. The company sold over 190,000 EVs in 2024, accounting for about 2% of China's passenger new energy vehicle market. It is also a leader in autonomous driving technology.